
ABSTRACT

NEW ADMINISTRATION REGIME FOR *N*-HYDROXY-4-{2-[3-(*N*,*N*-DIMETHYLAMINOMETHYL)BENZOFURAN-2-YLCARBONYLAMINO]ETHOXY}BENZAMIDE

N-hydroxy-4-{2-[3-(*N*,*N*-dimethylaminomethyl)benzofuran-2-ylcarbonylamino]ethoxy}-benzamide of formula (I):



(I),

or an addition salt thereof with a pharmaceutically acceptable acid or base, alone or in association with a surgery, chemotherapy, hormone therapy treatment or radiotherapy, for use in the treatment of cancer, characterised in that it is administered for 4 consecutive days, that period being followed by 3 consecutive days without any administration of compound of formula (I), with the proviso that chemotherapy is not FOLFOX.

Medicaments.